Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, et al.
Leukemia (2023) Vol. 37, Iss. 5, pp. 1048-1059
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Jorge E. Cortés, Koji Sasaki, Dong‐Wook Kim, et al.
Leukemia (2024) Vol. 38, Iss. 7, pp. 1522-1533
Open Access | Times Cited: 22
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
Elias Jabbour, Hagop M. Kantarjian
American Journal of Hematology (2024) Vol. 99, Iss. 11, pp. 2191-2212
Open Access | Times Cited: 21
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
Nicholas C.P. Cross, Thomas Ernst, Susan Branford, et al.
Leukemia (2023) Vol. 37, Iss. 11, pp. 2150-2167
Open Access | Times Cited: 41
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial
Jorge E. Cortés, Dong‐Wook Kim, Tapan Saikia, et al.
The Lancet Haematology (2025)
Closed Access | Times Cited: 1
Asciminib in the treatment of chronic myeloid leukemia in chronic phase
Alessandro Nanni Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.
Future Oncology (2025), pp. 1-17
Closed Access | Times Cited: 1
Resistance mutations in CML and how we approach them
Simona Soverini
Hematology (2023) Vol. 2023, Iss. 1, pp. 469-475
Closed Access | Times Cited: 13
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors
Lukas Veltmaat, Jorge E. Cortés
Blood (2024) Vol. 143, Iss. 10, pp. 858-865
Closed Access | Times Cited: 4
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia
Adi Shacham Abulafia, Yulia Volcheck, Martin Ellis, et al.
European Journal Of Haematology (2024)
Open Access | Times Cited: 4
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action
Akriti G Jain, Jorge E. Cortés
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Andreas Hochhaus, Dong‐Wook Kim, Jorge E. Cortés, et al.
Leukemia (2025)
Open Access
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results
Jorge E. Cortés, Fabian Lang, Delphine Réa, et al.
Leukemia (2025)
Open Access
Cytogenetic Response to Asciminib in Chronic Myeloid Leukemia With the e19a2 Micro BCR::ABL1 Transcript: A Case Report
Takuya Terakawa, Yasuhiro Shingai, Yoshiki Matsuoka, et al.
Cureus (2025)
Open Access
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population
Massimo Breccia, Antonella Russo Rossi, Valentina Giai, et al.
Hematological Oncology (2025) Vol. 43, Iss. 3
Open Access
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Andrew J. Innes, Chloe Hayden, Victoria Orovboni, et al.
Leukemia (2024)
Open Access | Times Cited: 3
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
Timothy P. Hughes, Giuseppe Saglio, Jan Geißler, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Cancer-associated thrombosis in hematologic malignancies
Masahiko Fukatsu, Takayuki Ikezoe
International Journal of Hematology (2024) Vol. 119, Iss. 5, pp. 516-525
Closed Access | Times Cited: 2
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
Lynette Chee, Nora Lee, Andrew Grigg, et al.
Internal Medicine Journal (2024) Vol. 54, Iss. 7, pp. 1214-1218
Open Access | Times Cited: 2
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
Ehab Atallah, Michael J. Mauro, Koji Sasaki, et al.
Future Oncology (2024), pp. 1-11
Open Access | Times Cited: 2
Clinical Pharmacology of Asciminib: A Review
Matthias Hoch, Felix Huth, Paul W. Manley, et al.
Clinical Pharmacokinetics (2024)
Open Access | Times Cited: 2
High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation
Yasuhiro Uchida, Daisuke Koyama, Kazuya Manabe, et al.
Internal Medicine (2023) Vol. 63, Iss. 5, pp. 717-720
Open Access | Times Cited: 5
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes
Nobuko Hijiya, Michael J. Mauro
Cancer Management and Research (2023) Vol. Volume 15, pp. 873-891
Open Access | Times Cited: 4
Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib
Zhijing Liu, Dongzhi Wu, Chengjie Ke, et al.
Oncology (2024), pp. 1-13
Closed Access | Times Cited: 1
Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison
Valentín García‐Gutiérrez, Fei Huang, Ajibade Ashaye, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies
Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 12, pp. 1720-1738
Closed Access | Times Cited: 3
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
Massimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 16, pp. 5267-5267
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top